SCHEMBL6039009

SCHEMBL6039009

COc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2OCCC2CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.61
KMT2A Q03164 6/20 0.61
KDM4E B2RXH2 3/20 0.57
LMNA P02545 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HPGD P15428 1/20 0.49
PIK3CG P48736 5/20 0.48
PIK3CD O00329 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038874 0.96 MEN1 (0.59) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038437 0.95 MEN1 (0.58) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038613 0.89 MEN1 (0.60) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038610 0.89 KDM4E (0.67) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038472 0.87 KMT2A (0.57) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038847 0.86 KMT2A (0.64) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038871 0.85 KDM4E (0.58) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038571 0.85 MEN1 (0.58) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038982 0.84 KDM4E (0.65) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038981 0.84 KDM4E (0.57) MEN1KMT2AKDM4ELMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 MEN1 2431/4885KMT2A 4190/4885KDM4E 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.